Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 11
---
 a particular date require a payment fromthe Selling Shareholder to us that exceeds $2,500,000, unless such limitation is waived bythe Selling Shareholder.

The Selling Shareholder is not obligated to buy any Depositary Shares pursuant to the Purchase Agreement if such Depositary Shares, when aggregated with all other securities then beneficially owned bythe Selling Shareholder and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder), would result inthe Selling Shareholder beneficially owning Ordinary Shares (represented by Depositary Shares) in excess of 9.99% of the then-outstanding Ordinary Shares, or the Beneficial Ownership Limitation.

The net proceeds under the Purchase Agreement to us will depend on the frequency and prices at which we sell Depositary Shares tothe
Selling Shareholder. We expect that any proceeds received by us from such sales tothe Selling
Shareholder will be usedto fund our development programs, for working capital and other
general corporate purposes.

We have the right to terminate the Purchase Agreement at any time, upon one business days’ notice, at no cost or penalty. During any “suspension event” under the Purchase Agreement,the Selling Shareholder does not have the right to terminate the Purchase Agreement; however, we may not initiate any regular or other purchase of shares bythe
Selling Shareholder, until such event of default is cured. In addition, in the event of bankruptcy proceedings by or against us, the Purchase Agreement will automatically terminate in accordance with its terms.

There are substantial risks to our shareholders as a result of the sale and issuance of Depositary Shares tothe Selling Shareholder
under the Purchase Agreement. These risks include substantial dilution, significant declines in our stock price and our inability to draw sufficient funds when needed. See “ Risk Factors.” The sale of our Depositary Shares tothe Selling Shareholder under the Purchase Agreement will not affect the rights or privileges of our other shareholders, except that the economic and voting interests of our existing shareholders will be diluted as a result of any such sale. Although the number of Depositary Shares that our other shareholders own will not decrease, the shares owned by our other shareholders will represent a smaller percentage of our total outstanding shares after any such sale tothe Selling
Shareholder under the Purchase Agreement.

For more information see “ The Committed Equity Financing.”

| 5 |

Promissory Note

On December 20, 202